Yuhan Corporation
http://eng.yuhan.co.kr/Main/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yuhan Corporation
Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
Trial Hot Spot: Australia's Attractions To The Korean Industry
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.
Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results
Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.
Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space
ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.
Company Information
- Industry
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Yuhan USA